5月29日，科济药业-B盘中上涨5.47%，报17.94港元/股，成交额4218.14万港元。消息面上，公司舒瑞基奥仑赛注射液获国家药品监督管理局纳入优先审评，核心管线审评加速为商业化前景提供重要催化。此外，港股生物科技板块今日整体回暖，信达生物涨9.69%、康方生物涨5.25%、三生制药涨4.46%，行业情绪修复带动前期因折价配股承压的个股迎来反弹。
科济药业控股有限公司主要从事开发CAR-T细胞疗法，覆盖血液恶性肿瘤、实体瘤及自身免疫性疾病领域，主要产品包括赛恺泽、舒瑞基奥仑赛注射液及通用型CAR-T细胞产品。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.